Article
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
Cancer research - 1 Oct 2018
Kas Sjors M, de Ruiter Julian R, Schipper Koen, Schut Eva, Bombardelli Lorenzo, Wientjens Ellen, Drenth Anne Paulien, de Korte-Grimmerink Renske, Mahakena Sunny, Phillips Christopher, Smith Paul D, Klarenbeek Sjoerd, van de Wetering Koen, Berns Anton, Wessels Lodewyk F A, Jonkers Jos
Abstract excerpt
In human cancers, FGFR signaling is frequently hyperactivated by deregulation of FGF ligands or by activating mutations in the FGFR receptors such as gene amplifications, point mutations, and gene fusions. As such, FGFR inhibitors are considered an attractive therapeutic strategy for patients with mutations in FGFR family members. We previously identified Fgfr2 as a key driver of invasive lobular carcinoma (ILC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.